United States
£ GBP
Label-free biosensors are devices that use biological or chemical receptors to detect analytes (molecules) in a sample. They give detailed information on the selectivity, affinity, and, in many cases, also the binding kinetics and thermodynamics of an interaction. Although they can be powerful tools in the hands of a skilled user, there is often a lack of knowledge of the best methods for using label-free assays to screen for biologically active molecules and accurately and precisely characterize molecular recognition events.
This book reviews both established and newer label-free techniques giving both the expert user and the general reader interested in the technologies and applications behind label-free an insight into the field from expert opinion leaders and practitioners of the technologies. Most importantly, chapters contain worked examples from leaders in the field that take the reader through the basics of experimental design, setup, assay development, and data analysis.
1. Label-free biosensors: an introduction Brian T. Cunningham; 2. Experimental design Robert Karlsson; 3. Extracting affinity constants from biosensor binding responses Rebecca L. Rich and David G. Myszka; 4. Extracting kinetic rate constants from binding responses Rebecca L. Rich and David G. Myszka; 5. Sensor surfaces and receptor deposition Matthew A. Cooper; 6. Macromolecular interactions Francis Markey; 7. Interactions with membranes and membrane receptors Matthew A. Cooper; 8. Application of SPR technology to pharmaceutical relevant drug-receptor interactions Walter Huber; 9. High-throughput analysis of biomolecular interactions and cellular responses with resonant waveguide grating biosensors Ye Fang, Jack Fang, Elizabeth Tran, Xinying Xie, Michael Hallstrom, and Anthony G. Frutos; 10. ITC-derived binding constants Richard K. Brown, Michael Brandts, Ronan O'Brien, and William B. Peters; 11. Impedance technology applied to cell-based assays Ryan McGuinness and Ed Verdonk.
Dr Matthew A. Cooper is Founder and Managing Director of Cambridge Medical Innovations and Co-Founder and Chief Scientific Officer of Akubio. Dr Cooper is consulted widely for biosensor, biotechnology, and pharmaceutical companies in the UK, Europe, and the United States. He is a review panel member for BBSRC, EPSRC, US NIH, US NIAID, and Science Foundation Ireland and a Fellow of the Royal Society of Medicine.
